Basilea Pharmaceutica Ag Stock Today
| BPMUF Stock | USD 52.83 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Basilea Pharmaceutica is trading at 52.83 as of the 31st of January 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 52.83. Basilea Pharmaceutica has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2024 and ending today, the 31st of January 2025. Click here to learn more.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. The company has 11.93 M outstanding shares. More on Basilea Pharmaceutica AG
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Basilea Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Basilea Pharmaceutica AG [BPMUF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Small-Cap' category with a current market capitalization of 626.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Basilea Pharmaceutica's market, we take the total number of its shares issued and multiply it by Basilea Pharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Basilea Pharmaceutica classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 11.93 M outstanding shares.
Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89.
Check Basilea Pharmaceutica Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Basilea Pharmaceutica is $626.06 Million. Basilea Pharmaceutica AG shows 3.07 percent of its outstanding shares held by insiders and 29.13 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Basilea Ownership Details
Basilea Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Basilea Pharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Basilea Pharmaceutica Corporate Management
| Lutz Wevelsiep | Head Affairs | Profile | |
| Adesh Kaul | Chief Officer | Profile | |
| Damian Heller | Gen Sec | Profile | |
| Gerrit Hauck | Chief Officer | Profile | |
| David Veitch | Chief Commercial Officer, Member of the Management Committee | Profile | |
| Ursula Eberhardt | Head HR | Profile | |
| Marc MD | Chief Officer | Profile |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.